VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA-Reference-Cited by-同舟云学术

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA

Published:2012-11 Issue:11 Volume:23 Page:2812-2820
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Martin L.K.,Li X.,Kleiber B.,Ellison E.C.,Bloomston M.,Zalupski M.,Bekaii-Saab T.S.

Funder

Genentech, Inc

Roche Group

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/11/2812/13786783/mds134.pdf

Reference76 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control;Weir;J Natl Cancer Inst,2003

3. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas;Muller;Am J Surg,2008

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

5. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297;Berlin;J Clin Oncol,2002

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer;Cancers;2024-04-20

2. Exploration of immune cell heterogeneity by single‐cell RNA sequencing and identification of secretory leukocyte protease inhibitor as an oncogene in pancreatic cancer;Environmental Toxicology;2024-03-13

3. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial;Frontiers in Immunology;2024-02-01

4. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198);European Journal of Cancer;2023-08

5. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy;Advances in Cancer Research;2023